Microsoft clearly has an expressed interest in the expansion of their life sciences division as indicated by the asset acquisition of Rosetta Biosoftware. Rosetta is a subsidiary of Merck & Co., Inc. Microsoft will be rolling Rosetta’s generic and data into their Amalga Life Sciences software. Through the acquisition, Merck will become a customer of Amalga.
“This agreement establishes a stable and sustainable platform for the Rosetta Biosoftware technology,” stated Merck Research Laboratories VP Rupert Vessey.
The deal will most likely close at the end of this month and the combined technologies should be available sometime in early 2010.